Abstract
Lopinavir/ritonavir plus indinavir was administered once daily as directly observed protease inhibitor-only therapy in 12 heavily pretreated HIV-1-infected patients with multiple virological failures and advanced immunosuppression (CD4 cell count 95 x 10 cells/microl). The treatment was well tolerated. At weeks 12, 24 and 48, most patients on treatment achieved viral suppression of less than 400 copies/ml and a corresponding median CD4 T-cell count increase. Pharmacokinetic data indicated therapeutic concentrations for both protease inhibitors in most patients.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Drug Administration Schedule
-
Drug Therapy, Combination
-
Female
-
HIV Infections / drug therapy*
-
HIV Protease Inhibitors / administration & dosage*
-
HIV Protease Inhibitors / blood
-
HIV-1*
-
Humans
-
Indinavir / administration & dosage*
-
Indinavir / blood
-
Lopinavir
-
Male
-
Middle Aged
-
Patient Compliance
-
Pilot Projects
-
Pyrimidinones / administration & dosage*
-
Pyrimidinones / blood
-
Ritonavir / administration & dosage*
-
Treatment Outcome
Substances
-
HIV Protease Inhibitors
-
Pyrimidinones
-
Lopinavir
-
Indinavir
-
Ritonavir